Profile data is unavailable for this security.
About the company
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
- Revenue in CHF (TTM)8.13bn
- Net income in CHF174.31m
- Incorporated2022
- Employees23.41k
- LocationSandoz Group AGCentralbahnstrasse 4BASEL 4051SwitzerlandCHE
- Websitehttps://www.sandoz.com/
More ▼
Mergers & acquisitions
| Acquired company | SDZ:SWX since announced | Transaction value |
|---|---|---|
| Just - Evotec Biologics EU SAS | 31.85% | 750.43m |
Data delayed at least 15 minutes, as of Feb 11 2026 16:31 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shionogi & Co Ltd | 2.32bn | 969.46m | 15.46bn | 4.96k | 15.26 | 1.96 | 14.40 | 6.68 | 228.94 | 228.94 | 546.70 | 1,779.33 | 0.2869 | 0.8648 | 2.76 | 93,915,640.00 | 11.98 | 12.17 | 13.13 | 13.74 | 84.50 | 84.91 | 41.78 | 38.30 | 5.21 | -- | 0.0148 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| United Therapeutics Corp | 2.40bn | 976.79m | 15.65bn | 1.31k | 17.92 | 3.08 | 15.05 | 6.51 | 26.41 | 26.41 | 64.94 | 153.61 | 0.4323 | 2.21 | 9.78 | 2,397,242.00 | 17.57 | 13.61 | 19.48 | 14.84 | 88.59 | 90.79 | 40.65 | 37.81 | 6.07 | -- | 0.00 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
| Royalty Pharma plc | 1.80bn | 587.56m | 19.60bn | 99.00 | 25.28 | 3.99 | 29.27 | 10.86 | 1.75 | 1.75 | 4.11 | 11.08 | 0.1257 | -- | 87.35 | 23,735,800.00 | 6.97 | 7.56 | 8.95 | 10.21 | -- | -- | 55.43 | 55.06 | -- | 6.91 | 0.4818 | 46.51 | -3.86 | 4.52 | -24.31 | -18.22 | 7.80 | -- |
| Biogen Inc | 7.60bn | 993.08m | 21.30bn | 7.50k | 21.46 | 1.52 | 13.38 | 2.80 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
| Hansoh Pharmaceutical Group Company Ltd | 1.46bn | 530.30m | 22.33bn | 9.31k | 41.41 | 6.36 | 39.00 | 15.27 | 0.9065 | 0.9065 | 2.50 | 5.90 | 0.3952 | 1.93 | 4.68 | 1,656,424.00 | 14.33 | 11.36 | 16.01 | 13.27 | 90.84 | 90.68 | 36.25 | 30.80 | 8.38 | -- | 0.0037 | 28.12 | 21.35 | 7.15 | 33.39 | 11.33 | -5.71 | -- |
| Astellas Pharma Inc | 10.25bn | 1.61bn | 22.79bn | 13.64k | 14.10 | 2.57 | 8.90 | 2.22 | 179.57 | 179.57 | 1,145.43 | 984.21 | 0.5841 | 1.27 | 2.90 | 151,038,200.00 | 9.15 | 3.05 | 14.11 | 4.45 | 81.00 | 81.15 | 15.67 | 5.42 | 0.839 | 41.32 | 0.2913 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
| Otsuka Holdings Co Ltd | 12.03bn | 2.23bn | 26.63bn | 35.34k | 11.70 | 1.82 | 9.47 | 2.21 | 842.65 | 842.65 | 4,540.85 | 5,413.66 | 0.64 | 2.11 | 4.86 | 68,439,860.00 | 12.01 | 5.91 | 15.12 | 7.27 | 71.72 | 69.18 | 18.76 | 9.89 | 1.65 | -- | 0.0695 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
| Sandoz Group AG | 8.13bn | 174.31m | 27.52bn | 23.41k | 157.72 | 3.98 | 47.59 | 3.38 | 0.3965 | 0.3965 | 18.78 | 15.73 | 0.5173 | 1.85 | 4.29 | 347,336.50 | 1.11 | -- | 1.60 | -- | 47.83 | -- | 2.14 | -- | 0.8178 | 7.37 | 0.3922 | -- | 4.06 | -- | -100.00 | -- | -- | -- |
| Daiichi Sankyo Co Ltd | 10.21bn | 1.52bn | 28.12bn | 19.77k | 18.23 | 3.23 | 14.92 | 2.75 | 163.62 | 163.62 | 1,103.05 | 924.09 | 0.5649 | 0.8183 | 3.11 | 103,827,400.00 | 8.38 | 5.72 | 10.55 | 7.11 | 77.54 | 72.15 | 14.84 | 11.03 | 1.85 | -- | 0.1495 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Teva Pharmaceutical Industries Ltd | 13.25bn | 1.08bn | 30.90bn | 31.17k | 28.50 | 5.02 | 16.72 | 2.33 | 3.73 | 3.73 | 45.87 | 21.19 | 0.431 | 2.64 | 5.10 | 1,704,929.00 | 3.50 | -1.47 | 5.25 | -2.08 | 52.72 | 50.58 | 8.13 | -4.04 | 0.8002 | 4.54 | 0.6799 | -- | 4.32 | 0.709 | 186.03 | -- | -2.82 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.47bn | 33.46m | 32.77bn | 2.23k | 1,411.75 | 181.99 | 427.19 | 13.29 | 0.2288 | 0.2288 | 24.38 | 1.77 | 0.7089 | 6.83 | 7.08 | 1,439,493.00 | 0.962 | -20.07 | 1.39 | -25.51 | 83.90 | 84.18 | 1.36 | -55.19 | 2.49 | 1.03 | 0.9146 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Sun Pharmaceutical Industries Ltd | 4.82bn | 889.72m | 34.74bn | 43.00k | 39.08 | -- | 30.57 | 7.21 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -104.79bn | -104.79bn | 37.37bn | 24.00k | -- | 2.26 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
Data as of Feb 11 2026. Currency figures normalised to Sandoz Group AG's reporting currency: Swiss Franc CHF
21.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 06 Jan 2026 | 25.00m | 5.68% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 16.31m | 3.71% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 10.97m | 2.49% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 7.63m | 1.74% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 7.61m | 1.73% |
| MFS International (UK) Ltd.as of 31 Dec 2025 | 6.35m | 1.44% |
| Vontobel Asset Management AGas of 31 Dec 2025 | 6.23m | 1.42% |
| Geode Capital Management LLCas of 05 Feb 2026 | 4.79m | 1.09% |
| DWS Investment GmbHas of 08 Jan 2026 | 4.62m | 1.05% |
| BlackRock Asset Management Deutschland AGas of 09 Jan 2026 | 4.19m | 0.95% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
